Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,19
KB0,56
PKN65,9665,971,06
Msft381,88381,970,43
Nokia4,74254,7465-0,05
IBM248,29248,51-0,17
Mercedes-Benz Group AG60,4560,47-0,49
PFE25,6125,62-1,50
12.03.2025 16:36:52
Indexy online
AD Index online
select
AD Index online
 

  • 12.03.2025 16:35:25
Penumbra (NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
269,75 2,82 7,41 125 290
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 12.03.2025
Popis společnosti
Obecné informace
Název společnostiPenumbra Inc
TickerPEN
Kmenové akcie:Ordinary Shares
RICPEN
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2024 4 500
Akcie v oběhu k 04.02.2025 38 515 949
MěnaUSD
Konstituent indexůS&P 400 Mid Cap
Kontaktní informace
UliceOne Penumbra Place
MěstoALAMEDA
PSČ94502
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon15 109 952 486
Fax13025313150

Business Summary: Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Penumbra Inc revenues increased 13% to $1.19B. Net income decreased 85% to $14M. Revenues reflect Vascular segment increase of 20% to $815.5M, United States segment increase of 19% to $902.1M. Net income was offset by Sales, General and Administrative -Other increase of 16% to $532.1M (expense), Research and Development - Other increase of 16% to $87.9M (expense).
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSSurgical and Medical Instrument Manufacturing
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICS2007Surgical & Medical Instrument Mfg
NAICS2007Electromedical Apparatus Mfg
NAICS1997Surgical and Medical Instrument Manufacturing
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
SICSurgical And Medical Instruments
SICElectromedical Equipment



  • Poslední aktualizace: 12.03.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerAdam Elsesser6201.01.2004
Chief Financial OfficerMaggie Yuen5202.12.201902.12.2019
Executive Vice President, General Counsel, SecretaryJohanna Roberts52
Chief Accounting OfficerLambert Shiu4402.12.201902.12.2019